N/A
N=70
Pharmacogenomic Testing to Personalize Supportive Oncology
Cancer · Depression · Pain
Bottom Line
View on ClinicalTrials.gov: NCT04500301 ↗Enrolled (actual)
70
Serious AEs
—
Results posted
Jan 2025
Primary outcome: Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Preemptive Pharmacogenomic Testing (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results |
9 | — |
Summary
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer. The investigators aim to understand how PGx testing can be used to improve medication management for pain and depression, and whether PGx-guided prescribing improves these symptoms and quality of life compared to historical controls.
Eligibility Criteria
Inclusion Criteria
- Written informed consent and HIPAA authorization for release of personal health information.
- Completion of ESAS at initial palliative medicine clinic visit, presenting with moderate to high pain (≥ 4/10) and/or depression (≥ 3/10).
- New patients ≥ 18 years of age who have had an initial visit in the Department of Supportive Oncology's palliative medicine clinic with hematologic malignancy or any stage solid tumor malignancy according to the provider.
- Agree to at least one additional palliative medicine clinic visit per protocol.
- Able to provide a buccal sample for PGx testing.
Exclusion Criteria
- Psychiatric illness, social situations, or active/recent (within 30 days) history of illicit substance (e.g. cocaine, heroin) abuse that would limit compliance with study requirements (e.g. clinic visits, medication compliance, etc.) as determined by the Investigator.
- Patients who have had prior multiple visits in palliative medicine clinic.
Data sourced from ClinicalTrials.gov (NCT04500301). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.